TORONTO, June 7, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces voting results from its Annual Meeting of Shareholders held in a virtual format on June 7, 2024.
A total of 21,098,254 Common Shares, or 66.32% of the total Common Shares issued and outstanding, were voted based on proxies and votes received at the meeting. Details of the voting by individual director were as follows:
Name of Nominee | Votes Cast FOR | % of Vote Cast | Votes WITHHELD | % of Votes |
John Welborn | 18,209,962 | 88.85 | 2,284,420 | 11.15 |
Craig Millian | 19,959,739 | 97.39 | 534,643 | 2.61 |
John Hanna | 19,135,935 | 93.37 | 1,358,447 | 6.63 |
Rodney Hill | 19,959,554 | 97.39 | 534,828 | 2.61 |
Laura Brege | 19,118,129 | 93.28 | 1,376,253 | 6.72 |
Norma Beauchamp | 16,442,226 | 80.23 | 4,052,156 | 19.77 |
Kyle Dempsey | 19,032,703 | 92.87 | 1,461,679 | 7.13 |
Christian Roy | 19,135,933 | 93.37 | 1,358,449 | 6.63 |
HLS also confirms that shareholders approved the appointment of Ernst & Young LLP as the Company's auditors with 21,098,117 votes (100%) cast "for" and 137 votes (0%) withheld.
Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com
Last Trade: | C$3.27 |
Daily Change: | 0.01 0.31 |
Daily Volume: | 1,732 |
Market Cap: | C$103.950M |
August 28, 2024 August 08, 2024 July 29, 2024 July 02, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB